Does Rallies show Form 4 insider transactions for MLTX?

Yes. Rallies tracks MLTX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is MLTX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for MLTX. It does not provide personalized investment advice.

MLTX (MoonLake Immunotherapeutics Class A Ordinary Shares) Stock Analysis - Insider Trades

MoonLake Immunotherapeutics Class A Ordinary Shares (MLTX) is a publicly traded Healthcare sector company. As of May 21, 2026, MLTX trades at $17.04 with a market cap of $1.21B and a P/E ratio of -4.82. MLTX moved +4.09% today. Year to date, MLTX is +52.37%; over the trailing twelve months it is -57.67%. Its 52-week range spans $5.95 to $62.75. Analyst consensus is buy with an average price target of $29.15. Rallies surfaces MLTX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading MLTX stock inside the company?

Recent MLTX insider activity includes Bodenstedt Matthias sold 13.65K, Bodenstedt Matthias sold 2.43K, Santos da Silva Jorge sold 51.87K, Santos da Silva Jorge sold 98.13K, and Bodenstedt Matthias sold 1.93K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

MLTX Key Metrics

Key financial metrics for MLTX
Metric	Value
Price	$17.04
Market Cap	$1.21B
P/E Ratio	-4.82
EPS	$-3.53
Dividend Yield	0.00%
52-Week High	$62.75
52-Week Low	$5.95
Volume	344
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-230.32M
Gross Margin	0.00%

Recent MLTX Insider Trades

Bodenstedt Matthias sold 13.65K (~$273.33K) on May 11, 2026.
Bodenstedt Matthias sold 2.43K (~$47.45K) on Apr 14, 2026.
Santos da Silva Jorge sold 51.87K (~$945.64K) on Apr 13, 2026.
Santos da Silva Jorge sold 98.13K (~$1.81M) on Apr 10, 2026.
Bodenstedt Matthias sold 1.93K (~$37.56K) on Apr 10, 2026.

Latest MLTX News

MoonLake’s Sonelokimab Delivers 62% HiSCR75 Week 40 But Stock Plunges 88% — Mar 31, 2026
Sonelokimab Delivers 81% Response in Phase 2 Axial Spondyloarthritis Trial — Feb 23, 2026
MoonLake’s Sonelokimab Delivers 81% ASAS40 Response; $394M Cash Fund Runs Into H2 2027 — Feb 22, 2026
MoonLake Immunotherapeutics Sees 42.6% Price Target Cut to $10, Gains FDA BLA Clarity — Jan 15, 2026
MoonLake Shares Jump 9.6% After Goldman Sachs Downgrade and Positive FDA Feedback — Jan 15, 2026

MLTX Analyst Consensus

14 analysts cover MLTX: 0 strong buy, 10 buy, 2 hold, 2 sell, 0 strong sell. Consensus rating is buy. Average price target: $29.15.

Common questions about MLTX

Who is trading MLTX stock inside the company?: Recent MLTX insider activity includes Bodenstedt Matthias sold 13.65K, Bodenstedt Matthias sold 2.43K, Santos da Silva Jorge sold 51.87K, Santos da Silva Jorge sold 98.13K, and Bodenstedt Matthias sold 1.93K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for MLTX?: Yes. Rallies tracks MLTX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is MLTX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for MLTX. It does not provide personalized investment advice.